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ABSTRACT
Photodynamic therapy (PDT) is a modality of cancer treatment in which tumor cells are destroyed by 
reactive oxygen species (ROS) produced by photosensitizers following its activation with visible or 
near infrared light. The PDT success is dependent on different factors namely on the efficiency of the 
photosensitizer deliver and targeting ability. In this review a special attention will be given to the role 
of some drug delivery systems to improve the efficiency of tetrapyrrolic photosensitizers to this type of 
treatment.
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INTRODUCTION
According to the World Health Organization, cancer 
is the second leading cause of death worldwide and 
for instance, it was estimated that 595,690 American 
citizens died from cancer in 2016, corresponding 
to about 1,600 deaths per day (Siegel et al. 2016). 
Nearly 13 million of cancer cases are diagnosed 
every year, and it is expected that the number of 
deaths will increase to 13.1 million in 2030 (Lucky 
et al. 2015).
The main types of cancer treatments 
include surgery, chemotherapy, radiotherapy 
and immunotherapy, either alone or using the 
combination of two or more of these therapies 
(Agostinis et al. 2011, Liu and Yang 2016, Miller 
et al. 2016). However, all these treatments have 
associated drawbacks. Chemotherapy is frequently 
related with several side effects, such as nausea, 
vomiting and diarrhea and it is usually accompanied 
by hair loss and alopecia (Krukiewicz and Zak 
2016, Sun et al. 2005, Tosti et al. 2005). Surgery, 
on the other hand, requires general anesthesia and 
several days or weeks of hospitalization, and a high 
recurrence rate is associated with surgical resection 
of tumors (Triesscheijn et al. 2006). The side 
effects of radiation therapy that may have dose-
limiting potential include diarrhea, mucositis, skin 
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toxicity, and xerostomia (Stubbe and Valero 2013). 
Consequently, further progresses are needed and a 
good approach consists in concentrating efforts on 
other known methodologies that are not yet fully 
appreciated.
Therefore, photodynamic therapy (PDT) has 
emerged as an important therapeutic approach 
to treat cancer, infections, and other diseases 
(Almeida et al. 2011, Alves et al. 2015, Gupta et al. 
2013, Hamblin and Mroz 2008, Van Hillegersberg 
et al. 1994, Spring et al. 2015). This methodology 
combines the action of light at an appropriate 
wavelength to activate special drugs called 
photosensitizers (PS); in addition, the presence of 
an adequate amount of molecular oxygen in the 
tissue is also required (Van Hillegersberg et al. 
1994). The excited PS generated by light activation 
then transfers its absorbed energy to molecular 
oxygen, generating cytotoxic reactive oxygen 
species (ROS), especially singlet oxygen (1O2) that 
oxidizes the target tissue, leading to permanent 
damage and provoking cell death by necrosis, 
apoptosis or autophagy (Van Hillegersberg et al. 
1994, Makky et al. 2011). However, since 1O2 owns 
a short half-life in water (~ 3 µs), it only causes 
photodamage in its direct vicinity (Castano et al. 
2004, Nosaka and Nosaka 2017). Therefore, the 
phototoxicity efficiency is highly dependent in the 
intracellular accumulation of the PS, as well as of 
its subcellular localization (Castano et al. 2004, 
Hamblin and Mroz 2008). So, in PDT the required 
three components on their own do not possess 
any toxic effect on the biological systems, unlike 
chemotherapy drugs that induce systemic toxicity, 
and the ionizing radiations of radiotherapy that 
damages neighboring normal tissues. 
PDT appears as a treatment modality for several 
types of diseases comprising superficial tumors, 
such as basal cell carcinomas, head and neck tumors, 
as well as tumors accessible to endoscopy, such as 
lung and esophageal cancers (Agostinis et al. 2011, 
Allison et al. 2005, Dolmans et al. 2003, Kadish 
et al. 2012, Saini et al. 2016, Toratani et al. 2016). 
Besides the oncological field, this methodology can 
also be applied in the inactivation of pathogenic 
microorganisms (Almeida et al. 2014, Alves et al. 
2011, Bonnett et al. 2006, Carvalho et al. 2007, 
Costa et al. 2010, Mesquita et al. 2014). One of 
the main benefits of the photodynamic approach 
on the inactivation of microorganisms is that it is 
improbable that mechanisms of resistance can be 
developed, due to the multi-target character of the 
photodynamic process (Costa et al. 2011, Mesquita 
et al. 2014, Tavares et al. 2010, 2011, Winckler 
2007). 
Succinctly, in PDT of tumors, the photoactive 
PS is firstly administered to the patient, followed 
by a waiting period for PS body distribution and 
selective retention by the tumor cells. Then, the 
tumor is exposed to light of appropriate wavelength 
to excite the PS molecules and to generate ROS 
responsible by cell death, damage of tumor 
microvasculature, or even induction of a local 
inflammatory reaction (Hu et al. 2011, Iranifam 
2014).
A high number of PSs that are being considered 
in clinical or in PDT experimental studies are based 
on derivatives of protoporphyrin IX, the free-base 
of heme, the prosthetic group of  hemoproteins like 
hemoglobin. These derivatives present significant 
photoactivity and the drug biodistribution and 
pharmacokinetics are dependent on the peripheral 
substituents and on their composition (Agostinis 
et al. 2011, Bonnett 1995, Makky et al. 2011). 
The first formulation approved for PDT of cancer 
under the trade name of Photofrin (also known 
as Photosan or Porfimer Sodium) is based on this 
type of PSs, justifying the special attention given 
to natural or synthetic porphyrins and analogues 
(Agostinis et al. 2011, Castano et al. 2004, DeRosa 
and Crutchley 2002, Erzinger et al. 2011, Kadish et 
al. 2012, Ormond and Freeman 2013).
Therefore, the main advantages of PDT 
over other conventional cancer treatments are: 
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(i) low systemic toxicity due to the fact that 
PS is only activated in the presence of light; (ii) 
ability to destroy tumor cells selectively; (iii) can 
be applied alone or in combination with other 
therapeutic modalities, such as chemotherapy, 
surgery, radiotherapy or immunotherapy; and (iv) 
it is often cheaper than other cancer treatments 
(Chilakamarthi and Giribabu 2017, Juarranz et al. 
2008). Despite the aforementioned advantages, 
PDT possesses also some drawbacks: (i) the PS 
often used in the treatment are water-insoluble 
molecules, and consequently their injection into 
the body is not easy; (ii) patients who are treated 
with the available PS may get sensitive to light for 
a while, thus light exposure precautions must be 
taken after the treatment; (iii) lack of PS target-
cell specificity; and (iv) limited light penetration 
in the tissues if the conventional light (600–700 
nm) is used because it cannot penetrate deeper than 
10 mm into the skin to reach the tumor site, thus 
limiting PDT to treat only superficial tumors such 
as skin cancer, nasopharyngeal cancer and oral 
cancer (Hu et al. 2011, Huang et al. 2013, Iranifam 
2014, Laptev et al. 2006, Theodossiou et al. 2003). 
Nevertheless, PDT has been used to treat other 
types of cancer such as digestive tumors, prostate 
cancer and brain tumors (Agostinis et al. 2011).
Ideally, a PS agent should be a single and pure 
compound that preferentially accumulates in tumor 
tissue, with insignificant dark toxicity, thereby 
minimizing phototoxic side-effects and rapidly 
clearing from the normal tissue (Agostinis et al. 2011, 
Bonnett 1995, Juarranz et al. 2008). Amphiphilicity 
is another feature that PS must possess because 
when the PS is systemically administered it 
requires some degree of hydrophilicity. However, 
in order to the PS bind to target cells, some degree 
of lipophilicity is needed. Additionally, they must 
have good photophysical properties such as high 
quantum yields of triplet state formation, high 
singlet oxygen production and also a suitable triplet 
lifetime to interact with ground state oxygen or 
other substrates, to generate an appropriate amount 
of ROS (Agostinis et al. 2011, Allison and Sibata 
2010, Juarranz et al. 2008). Most importantly, PSs 
should have good absorption on the therapeutic 
window, between 600 and 800 nm (red to deep red 
region of the electromagnetic spectrum); photon 
absorption at wavelengths greater than 800 nm 
does not offer enough energy to excite molecular 
oxygen to its singlet state, one of the main ROS 
formed upon irradiation. Consequently, since the 
penetration of light into tissue is enhanced with 
its wavelength, agents with strong absorbance in 
the red region, such as chlorins, bacteriochlorins 
and phthalocyanines (Figure 1) can offer an 
improvement in tumor control (Agostinis et al. 
2011). However, the majority of existing PSs 
do not satisfy all of these requirements; it is 
recognized that an important focus must be given 
to the development of PSs that can be activated 
with light of longer wavelength, causing shorter 
generalized photosensitivity and, more importantly, 
that possess high tumor specificity. 
Figure 1 - Structures of some nucleus present in natural 
and synthetic PSs used in PDT.
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One of the main challenges in PDT as in other 
therapies is related with the drug delivery (Master 
et al. 2013, Ogawara and Higaki 2017). For an 
efficient PDT treatment, it is essential that the PS 
will be delivered in therapeutic concentrations to 
the target cells with little or no uptake by non-target 
cells, thus minimizing undesirable side-effects in 
healthy tissues (Gupta et al. 2013, Ogawara and 
Higaki 2017). As the majority of effective PSs 
are highly hydrophobic, several encapsulation 
approaches have been considered to minimize the 
formation of inactive aggregates in an aqueous 
environment (Krasnovsky et al. 1994, Master et al. 
2013, Ogawara and Higaki 2017, Tada and Baptista 
2015). It is well known that aggregation reduces the 
efficiency of the PS, which must be in monomeric 
form to be photoactive (Konan et al. 2002). Many 
of delivery systems are based on nanoparticles 
(NP) or other nanostructures (Chatterjee et al. 2008, 
Master et al. 2013). NPs, with a size ranging from 
1 to 100 nm, reveal unique physical and chemical 
properties and are being exploited to deliver PSs, 
in order to improve the current treatment regimens 
in PDT (Chatterjee et al. 2008, Konan et al. 2002, 
Master et al. 2013, Ogawara and Higaki 2017). 
In this revision it will be discussed the 
biological effectiveness of some drug delivery 
systems in PDT of cancer, namely the ones related 
with liposomes formulations, silica and gold NPs 
and polymeric micelles. In Figure 1 are represented 
some structures of the nucleus present in natural 
and synthetic PSs that will be referred along this 
review. We would like to mention that no attempt 
was made to cover all types of formulations and 
papers concerning this topic, but to show the 
essential features of the selected nanocarriers and 
how a PDT treatment can be improved by their use. 
THE DRUG DELIVERY SYSTEMS 
IN PDT OF CANCER
The use of nanotechnology in PDT is responsible 
for new advances in this field by providing efficient 
nanoscale PSs delivery systems, which are able to 
improve the treatment efficacy and to minimize 
many side effects associated with classic PDT. NPs 
were probably first conceptualized by Birrenbach 
and co-worker (Birrenbach and Speiser 1976). 
As aforementioned, they are an umbrella term for 
nanospheres and nanocapsules with diameters less 
than 100 nm (Gupta et al. 2013). The potential 
interest in NPs as drug carriers has been increasing 
in recent years due to several reasons: (i) they can 
transport hydrophobic drugs in blood; (ii) their 
surface area can be modified with functional groups 
for additional chemical/biochemical properties; 
(iii) a controlled release of drug is possible; (iv) 
they have large distribution volumes and are 
generally taken up efficiently by cells; and finally 
(v) a high number of different synthetic strategies 
are available (Calixto et al. 2016, Couvreur et al. 
1986, Florence and Hussain 2001, Gupta et al. 
2013).
Molecules based on hydrophobic cores like 
porphyrins and analogues own very poor solubility 
in aqueous media causing certain limitations for 
their potential use in PDT (Temizel et al. 2014). 
Despite accomplishing a better solubility of the PS 
with the incorporation of some water solubilizing 
groups, such as HSO3
−, COO− and NR4
+ on the PS 
peripheral positions, the delivery of hydrophobic 
PSs to the tumor cells is still an important PDT goal 
(Derycke and de Witte 2004, Postigo et al. 2004). 
Besides the PS water solubility issue, undesired 
PS interactions with proteins or biomolecules in 
aqueous medium are also a concern in clinical 
applications of PDT. On the other hand, the 
hydrophobicity of the cell membrane can hinder 
the approach of the ionized PS toward the cells 
(Temizel et al. 2014). All these obstacles are 
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responsible for the special attention given by the 
scientific community to the PSs cell distribution 
by different vehicles (Calixto et al. 2016, Chen 
et al. 2005, Dragicevic-Curic et al. 2009, Namiki 
et al. 2004). Common approaches used for the 
formulation of PSs are based on the encapsulation 
of the photosensitizing agent in colloidal carriers, 
such as oil-based dispersions (Allémann et al. 
1997, Biolo et al. 1996, Chen et al. 2005, Feofanov 
et al. 2002, Wöhrle et al. 1999), micelle systems 
(van Nostrum 2004), liposomes (Chen et al. 2005, 
Derycke and de Witte 2004), biodegradable NPs 
(Allémann et al. 1995, 1996, Konan et al. 2003, 
Stevens et al. 2004), and also on the conjugation 
of the PS with hydrophilic polymers such as 
polyethylene glycol (PEG) (Brasseur et al. 1999, 
Fehr et al. 2000, Hamblin et al. 2001) or polylysine 
(Hamblin et al. 1999, 2003, Silva et al. 2006, 2010, 
Soukos et al. 1997). As it was already mentioned, 
in the next sections the main focus will be given to 
the most commonly types of NPs used to deliver 
porphyrins and analogues and how these systems 
affect the efficiency of the photodynamic treatment. 
Figure 2 summarizes the structures of important 
PSs studied by different groups to evaluate the 
importance of the drug delivery in PDT efficacy. 
LIPOSOMES
Liposomes are found to be one of the most 
efficient vehicles to carry hydrophobic molecules 
in aqueous medium (Bader et al. 1984, Medina 
et al. 2004). They are vesicles with one or more 
concentric phospholipid bilayer(s), making them 
biocompatible due to their lipid composition 
(Figure 3a and 3b). Similar to any bilayer membrane 
structure, liposomes possess two compartments: an 
aqueous core (hydrophilic) and a lipophilic space 
among the lipid bilayer (hydrophobic) as it can 
be observed in Figure 3a (Banerjee 2001, Chen 
et al. 2005). Thus, this provides the flexibility to 
encapsulate both hydrophilic and hydrophobic 
molecules, which can be seen as an advantage. They 
can simply encapsulate the hydrophobic molecules, 
during the bilayer formation, into the lipophilic 
space due to their hydrophobic ends (Decker et al. 
2012). Consequently, loaded liposomes can easily 
transport the hydrophobic drug in aqueous medium 
to the target tissue and the similarity between their 
structures and the cell membrane, allows an easy 
diffusion and the drug unload into the cytoplasm 
(Salvati et al. 2007). Additionally, their nanometric 
size (classically 60-120 nm) confer them a high 
loading capacity of the therapeutic agent. All these 
properties make this type of systems effective 
vehicles for the delivery of drugs in PDT (Banerjee 
2001, Chen et al. 2005, Sneider et al. 2017).
Certain improvements in liposomal technology 
and molecular biology have been done, allowing 
them to have targeting power in order to achieve 
selective delivery to specific biological targets 
(Medina et al. 2004). In fact, the accumulation 
of liposomes in the tumor tissue is mostly due to 
the leakage of tumor blood vessels and also to the 
impairment of the lymphatic systems exhibited 
by most tumor tissues (Jain 2001). Leaky blood 
vessels allow more liposomes to diffuse through 
the vasculature, and the impairment of the 
lymphatic system leads to a continued retention/
uptake of liposomes in the tumor interstitial area. 
This enhanced permeability and retention effect 
(EPR) is the main explanation for the selective 
tumor accumulation of liposomes (Chen et al. 
2005, Maeda 2001). Despite the efficiency shown 
by these vehicles, any liposomal formulation needs 
to balance the liposomal stability in the circulation 
with drug availability/release once it reaches the 
target tissue (Drummond et al. 1999). Under perfect 
conditions, the photosensitizing agents are stably 
preserved in a liposome and are then selectively 
released in the target tissue. However, it is known 
that the drugs’ physicochemical properties, as well 
as the tissue environment and liposomal structures 
can affect the liposomal stability and consequently 
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Figure 2 - Structures of the main PSs discussed in the next sections of this review.
may influence the release of the therapeutic agents 
from these vehicles (Al-Ahmady et al. 2016, Luo 
et al. 2016). 
Highly hydrophilic drugs can be stably carried 
within the liposomal aqueous compartment while 
in circulation, but low membrane diffusion can 
restrict the release of these drugs into the target 
tissue. These drugs tend to associate with lipid 
components of liposomes and to be redistributed 
to plasma proteins before reaching the target 
tissue. On the other hand, amphiphilic drugs are 
being considered the most suitable for liposomal 
formulation. The structure of the liposome can 
also affect the liposomal stability and the drug 
release. The presence of cholesterol and saturated 
phospholipids increases the rigidity of liposomes 
but reduces the drug release, while liposomes 
comprising additional fluid lipid components 
can easily break up and release the drug during 
circulation (Drummond et al. 1999).
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In several studies, liposomes with a high 
loading capacity and flexibility to encapsulate 
PSs, such as porphyrin derivatives or analogs 
(Figure 2), have been used as delivery systems for 
improving the efficiency of PDT (Cordeiro et al. 
2012, Damoiseau et al. 2001, Deng et al. 2013a, 
Kepczyński 2002, Nam et al. 2017, Polo et al. 
1995, Temizel et al. 2014). 
Hematoporphyrin (Hp) or its derivative 
(HpD) and Photofrin (a partially purified 
form of HpD) (Figure 2) were the first PSs to 
be encapsulated in liposomes based on L-α-
dipalmitoylphosphatidylcholine (DPPC) (Figure 
3b) (Cozzani et al. 1985, Spikes 1983). For 
instance, the incubation of HeLa cells with 
equivalent concentrations of either Hp in aqueous 
solution, or Hp and its dimethylester encapsulated 
in unilamellar liposomes showed that the liposomal 
porphyrins were able to bind to cells at a higher 
rate and in a significantly larger amount than the 
Figure 3 - a. Schematic representation of a unilamellar and multilamellar liposome 
comprising lipid soluble PS in hydrophobic lipid bilayer; and b. Structures of the most 
employed phospholipids used to prepare liposomes for drug delivery proposes.
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aqueous solutions of Hp. Also, the release of the 
porphyrins from the cells into the cell culture 
medium was remarkably reduced and slower with 
the liposomal porphyrins. The study showed that 
the photodamage occurred preferentially in the 
cytoplasmic membrane and in the membranes of cell 
organelles and the PDT efficiency was remarkable 
increased when both PS were incorporated in 
liposomes (Cozzani et al. 1985). A similar situation 
was reported when Hp encapsulated in the same 
liposomes was injected in tumor-bearing mice; 
longer tumor retention and significantly higher 
tumor selectivity were observed (Jori et al. 1983). 
On the other hand, Li et al. (Jiang et al. 1997, 1998) 
encapsulated Photofrin (Figure 2) in an unilamellar 
DPPC liposome and compared the tumor drug 
uptake and PDT response with Photofrin delivered 
in a dextrose solution. They found that liposomal 
Photofrin led to an improvement in the tumor 
drug uptake and even produced more tumor 
injury than Photofrin in dextrose, in both 9L rat 
gliosarcoma (Jiang et al. 1997) and U87 human 
glioma xenograft in athymic nude rats (Jiang et 
al. 1998). However, the damage to regular brain 
tissue was comparable between the two delivery 
systems. Similar results were obtained in a human 
gastric cancer xenograft using Photofrin (Figure 
2) entrapped in multilamellar liposomes composed 
of L-α-dimiristoylphosphatidylcholine (DMPC) 
and dimyristoylphosphatidylglycerol (DMPG) 
and cholesterol (Figure 3b) (Igarashi et al. 2003). 
The results showed that liposome formulation is 
responsible for a higher concentration of PS in 
the tumor when compared with non-liposomal 
Photofrin, resulting in an improvement of the PDT 
efficacy. 
Knowing that the preservation of the PS 
monomeric state is an important feature for an 
effective generation of 1O2, liposomal formulations 
have been also extensively used to improve the 
PDT efficiency of other natural types of porphyrins 
(Bachor et al. 1995) or of synthetic porphyrins such 
as 5,10,15,20-tetraphenylporphyrin (TPP) (Figure 
2) (Ježek et al. 2003, Lovčinský et al. 1999) and 
dimers linked by an amide bond based on meso-
tetraarylporphyrins (Faustino et al. 1997, 2000), 
chlorins, bacteriochlorins and phthalocyanines, as 
it was revised by Chen et al. (Chen et al. 2005).
An interesting publication related with 
synthetic porphyrins was reported in 2004, 
by Postigo et al. (Postigo et al. 2004). The 
authors studied the incorporation of TPP and 
5,10,15,20-tetrapyridylporphyrin (TPyP) (Figure 
2) and of their Zn(II) and Mn(III) complexes 
in intermediate unilamellar liposomes and 
multilamellar vesicles using different lipid/
porphyrin ratios. The phospholipids selected were 
L-α-palmitoleoylphosphatidylcholine (POPC), 
DPPC, DMPC and L-α-dioleoylphosphatidylserine 
(OOPS) (Figure 3b) and it was showed that the 
incorporation of porphyrins into the carriers could 
be related to their ability to form aggregates in 
aqueous media; it was found that the Zn(II) complex 
of TPP with less tendency to aggregate, was 
efficiently incorporated into liposomes. So, it was 
claimed that hydrophobic porphyrin derivatives 
structures with less tendency to aggregate than 
that TPP complex can be efficiently incorporated 
into liposomes, and consequently can be useful for 
clinical applications (Postigo et al. 2004). 
In  another  s tudy,  car r ied  ou t  by 
Nawalany et al. (Nawalany et al. 2009), 
other photosensitizing systems based on 
the synthetic meso-tetraarylporphyrins: (1) 
5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin 
(p-THPP) encapsulated in sterically stabilized 
liposomes (N-[methoxy(polyethyleneglycol)2000]
c a rbony l -1 ,2 -d ipa lmi toy l - sn - g lyce ro -3 -
phosphoethanolamine sodium salt) and (2) p-THPP 
covalently attached to polyethylene glycol (PEG2000) 
were studied in vitro (Figure 4a). The dark and 
photocytotoxicity of both systems were evaluated 
on two cell lines: a human colorectal carcinoma cell 
line (HCT 116) and a prostate cancer cell line (DU 
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145), and compared with free p-THPP. The results 
showed that both pegylation and incorporation in 
the sterically stabilized liposomes were able to 
reduce efficiently the dark cytotoxicity of the parent 
porphyrin. Moreover, the pegylated porphyrin 
dissolved in culture medium was less readily 
taken-up by cells than the porphyrin encapsulated 
in liposomes, probably due to formation of large 
polymeric clusters. Additionally, the liposomal 
formulation showed higher photocytotoxicity than 
p-THPP–PEG2000 towards both cell lines, but the 
overall phototoxicity efficiency was dependent on 
the type of the cancer cell line (Nawalany et al. 
2009).
Another study concerning the use of a 
synthetic porphyrin was recently reported by 
Nam et al. (Nam et al. 2017). The hydrophobic 
5,10,15,20-tetrakis(benzo[b]thiophene)porphyrin 
(Figure 4b) was incorporated into various 
compositions of liposomes (DOPC, DPPC, 
phosphatidylserine and phosphatidylinositol, 
Figure 3b) and the PDT efficacy of the liposomal 
compositions was evaluated against MCF-7 
cells (Nam et al. 2017). Although all liposomal 
compositions displayed photodynamic efficiency, 
the one prepared with DOPC was the most 
promising. After irradiation, this formulation was 
also the one that exhibited higher intracellular 1O2 
generation, the main responsible of cancer cell 
death. 
In a research work carried out in 2014 by 
Temizel et al. (Temizel et al. 2014), it was studied 
the photodynamic activity of protoporphyrin IX 
(PpIX) (Figure 2) bearing lipophilic oleylamine 
arms (PpIX-Ole) (Figure 5) before and after 
being encapsulated into 1,2-dioleoyl-sn-glycero-
phosphatidylcholine (DOPC) liposomes (Figure 
3b).  The photodynamic studies of the liposomal 
materials were performed in the presence of cancer 
cell lines HeLa and AGS, under irradiation with 
UV light 375 nm (10 mW).  It was found that both 
PpIX-Ole-DOPC and PpIX-Ole are much more 
effective than the non-functionalized PpIX and the 
results were due to the drug delivery characteristic 
of the liposome, which showed an effective role in 
endocytosis. In the same study it was also reported 
Figure 4 - a. Structure of 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin (p-THPP) and of the derivatives substituted by PEG2000; 
b. Structure of 5,10,15,20-tetrakis(benzo[b]thiophene)porphyrin.
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that under light conditions, liposomal PpIX-Ole is 
able to induce more apoptosis in AGS cells than 
in HeLa cells, being this situation related to the 
permeability of the cells (Temizel et al. 2014). 
SILICA NANOPARTICLES
As it was mentioned earlier, some PSs can 
aggregate and consequently the effectiveness of 
photoinactivation can be affected (Darwent et al. 
1982). Taking this aspect in consideration, several 
studies concerning biomedical applications have 
been focused on the incorporation of PSs into 
silica NPs (SiNP) once they are suitable carrier for 
bioactive molecules by preventing or minimizing 
the aggregation phenomena or their degradation 
under physiological conditions (Couleaud et al. 
2010, Lin et al. 2011, Oluwole and Nyokong 2017, 
Tang and Cheng 2013). In clinical field, SiNPs are 
used as cell markers (Huang et al. 2005, Lin et 
al. 2006, Wu et al. 2008), drug and gene delivery 
platforms (Lu et al. 2007, Tsai et al. 2008), enzyme 
adsorption and immobilization (Popat et al. 2011), 
and they are also able to internalize into cells per 
si (Huang et al. 2005, Lin et al. 2006, Wu et al. 
2008). For application in PDT, silica based NPs 
such as organically modified silica (ORMOSIL), 
mesoporous silica NPs (MSiNP) and hollow SiNPs 
(HSiNP) are commonly employed. These SiNPs 
are especially suitable for PDT because they are 
vehicles of great chemical inertness, immune to pH 
variations, structurally stable, transparent to light 
and allow to keep the attached PS in monomeric 
form, preventing self-aggregation in physiologic 
conditions. Besides that, molecular oxygen and 1O2 
can diffuse in and out through the shell of SiNP 
(Chouikrat et al. 2012, Stallivieri et al. 2016). 
Moreover, SiNPs can be easily prepared from 
a variety of precursors and synthetic routes in 
different size, shape and porosity and its surface 
can be decorated with several tumor-cell targeting 
vectors, such as PEGs, antibodies, peptides, 
glycosides among several other possibilities 
(Couleaud et al. 2010, Lucky et al. 2015, Piao et 
al. 2008). 
ORMOSIL based NPs have been extensively 
used due to their flexible hydrophobic/hydrophilic 
properties, which can overcome the problem 
associated with the degree of hydrophobicity of the 
PS. Moreover, ORMOSIL can possess functional 
groups added to the surface that make these SiNPs 
promising vectors for PDT applications (Couleaud 
et al. 2010). For instance, Ohulchanskyy et al. 
were able to prepare ORMOSIL NPs with a PS 
molecule covalently incorporated into the SiNP 
aiming to minimize the PS release during systemic 
circulation (Ohulchanskyy et al. 2007). In this 
study, the precursor for ORMOSIL with the linked 
PS iodobenzylpyropheophorbide (Figure 6) was 
first prepared to promote its co-precipitation with 
the ORMOSIL precursor vinyltriethoxysilane. The 
PS-conjugated to ORMOSIL and an ORMOSIL 
encapsulated PS were tested against two tumor 
cells Colon-26 and RIF-1 cell lines. The results 
demonstrated that in addition to the preservation of 
the photophysical properties by the PS-conjugated 
ORMOSIL, an avidly uptake was observed by 
this conjugate and a significant phototoxicity 
in treated cells upon light irradiation. Moreover, 
the authors highlighted the fact that the presence 
of the iodine atom on the PS molecule allows its 
chemical replacement by a radiolabeled iodine 
Figure 5 - Structure of Protoporphyrin IX functionalized with 
lipophilic oleylamine.
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atom (e.g. I-124, I-125, etc.), thus converting these 
NPs in contrast agents for PET/SPECT imaging 
while preserving their therapeutic functionality 
(Ohulchanskyy et al. 2007). Similar photodynamic 
behavior was observed by other research 
groups involving other PSs covalently linked or 
encapsulated in ORMOSIL NPs (Tang et al. 2007).
Managa et al. reported the covalent attachment 
of Zn(II), Ga(III) and Si(IV) complexes of 
5-(4-(4-carboxyphenyl)oxyphenyl)-10,15,20-
triphenylporphyrin (Figure 7) by an ester linkage 
to SiNPs in the presence of the polymeric matrix 
Pluronic 127. Although the 1O2 quantum yield 
suffered a slightly decrease upon conjugation, 
the photodynamic efficiency of the materials 
was improved when compared with the non-
incorporated complexes and the best results were 
obtained with the Zn(II) derivative (Managa et al. 
2016).
The efficacy of protoporphyrin IX (Figure 2) 
encapsulated in SiNPs of different sizes (10, 25 and 
60 nm) was evaluated in vitro against six cancer cell 
lines (colon cancer cell lines HCT-116 and HT-29, 
breast cancer cell lines MCF-7 and MDA-MB-231, 
epidermoid cell line A431 and the lymphoblastoid 
cell line LLBC37) by Simon et al. in 2010 (Simon 
et al. 2010). The authors observed that for all the 
cell lines a better efficiency of photosensitization 
was reached when the PS was incorporated in the 
NPs. In the in vivo tests performed in HCT116, 
A549 and glioblastoma multiforme tumor-bearing 
mice, the uptake of protoporphyrin IX encapsulated 
in SiNP was high and its accumulation in skin 
was markedly lower when compared with tumor 
(Simon et al. 2010).
Gianotti et al. (Gianotti et al. 2016) used 
mesoporous SiNPs (MSiNPs) to covalently 
conjugate verteporfin (Figure 2), a clinically 
approved PS of second generation (Figure 8). 
The conjugates were prepared with three different 
concentrations of verteporfin (nominal loading of 
10, 40 and 100 mg/g), and the highest photodynamic 
efficiency was obtained with the intermediate 
loading system (40 mg/g). The biological evaluation 
Figure 6 - Structure of the precursor 
for  ORMOSIL with the l inked PS 
3-iodobenzylpyropheophorbide.
Figure 7 - Structure of 5-(4-(4-carboxyphenyl)oxyphenyl)-
10,15,20-triphenylporphyrin complexed with Zn(II), Ga(III) 
and Si(IV) used to link to pluronic SiNPs.
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of this conjugate was assessed in HeLa cells after 4 
h of incubation and the results showed that the cell 
viability was dramatically reduced after 60 s of red 
light irradiation (Gianotti et al. 2016).
Zhang et al. (Zhang et al. 2016) constructed a 
drug delivery system also based on MSiNPs for the 
co-delivery of cisplatin and chlorin e6 (Figure 2). 
The principal aim of the study was to circumvent 
the cisplatin resistance problem by combining the 
chemotreatment with PDT. The new drug delivery 
system was tested in lung cell lines non-cisplatin 
resistant (A549) and cisplatin resistant (A549R). 
The study showed that the MSiNPs bearing cisplatin 
and chlorin e6 were efficiently internalized by cells 
through endocytosis and released into cytoplasm 
resulting on remarkable high cellular levels of ROS, 
after 660 nm light irradiation (10 mW/cm2) (Zhang 
et al. 2016). This combined chemo-photodynamic 
therapy achieved very efficient anticancer activity 
against cisplatin-resistant A549R lung cancer 
cells with much lower IC50 values (0.53 µM) that 
cisplatin alone (25.1 µM). 
Chen et al. (Chen et al. 2016b) followed a 
slightly different approach to build nanoplatforms 
based on MSiNPs to deliver the bioreductive 
prodrug tirapazamine (TPZ) and the Gd3+ complex 
of tetrasulfonated porphyrin (TPPS4) (Figure 2). 
It was expected that the cytotoxicity of TPZ to 
hypoxic cells, could complement the PDT action, 
due to tumor hypoxic environment intensified 
by the photochemical reaction during PDT. The 
nanoplatforms were prepared using negatively 
charged per-O-methyl-β-cyclodextrin-grafted-
hyaluronic acid (HA-CD) and the Gd3+ complex of 
5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin 
alternatively deposited onto TPZ-MSiNPs via a 
layer-by-layer (LbL) assembly strategy (Figure 9). 
The efficacy of the drug delivered platform 
was assessed on three cell lines (Squamous 
cell carcinoma cell line SCC-7, Human breast 
adenocarcinoma cell line MCF-7 and African 
green monkey kidney fibroblast cells COS-
Figure 8 - Schematic representation of the synthetic procedure 
used to obtain Verteporfin-MSiNPs. Reproduced from 
(Gianotti et al. 2016) with permission of John Wiley and Sons.
Figure 9 - The theranostic nanoplatform of TPPS4 on TPZ-
MSiNPs.
7) and also in vivo using BALB/c nude mice 
inoculated in the back hind leg with SCC-7 cells. 
The biological assessment studies showed a 
preferential accumulation of the nanoplatform in 
the tumor site and a significant inhibition of tumor 
progression by this combined action of PDT and 
bioreductive chemotherapy (Chen et al. 2016b). 
The enhanced synergistic effect was also intuitively 
confirmed by the final average tumor weight and 
the corresponding tumor images.
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Teng et al. (Teng et al. 2013) selected also 
MSiNPs as the drug deliver platform for their PDT 
studies. The authors loaded PpIX (Figure 2) in 
MSiNPs sensitized with fluorescein isothiocyanate 
(FITC) and with a phospholipid derivatized with 
folate. The prepared deliver platform enhanced 
the in vitro phototoxicity against HeLa cells and 
diminished dark toxicity when compared with 
the free PpIX. The in vivo study performed on 
subcutaneous melanoma in nude mice inoculated 
with B16F10 cells, also presented the ability of 
this nanocarrier system to mitigate nearly 65% 
of tumor growth (Teng et al. 2013). It was also 
commented that the co-loading of PpIX and FITC 
in the nanoPDT system provided an insight into the 
therapeutic mechanism by tracking their fluorescent 
emissions.
Taking advantage that some materials can 
convert absorbed lower-energy photons (with less 
energy than the singlet energy level of molecular 
oxygen) to higher-energy photons through 
excitation with multiple photons process, Xu et al. 
(Xu et al. 2016) constructed a nanoplatform based 
on mesoporous silica coated with NaYF4:Yb/Er and 
then soaked with an aqueous solution of vitamin B12 
(the selected PS), for 24 h. The biological results 
obtained showed that the nanoplatform containing 
vitamin B12 exhibited a significant photodynamic 
effect on human breast cancer cell line (MDA-
MB-231) under near-infrared irradiation (980 nm) 
(Xu et al. 2016).
The high capacity of hollow SiNPs (HSiNPs) 
to load PSs into their cavities was also considered 
in several publications once the required PS 
concentrations in the tumoral region can be attained 
faster when compared with other nanoplatforms. For 
instance, Deng et al. demonstrated the superiority 
of Photosan (Figure 2) loaded into HSiNPs when 
compared with the free PS in the photodamage 
of cholangiocarcinoma cells QBC939 (Deng et 
al. 2013b). Parameters such as photostability and 
generation of 1O2 were significantly enhanced by 
the encapsulation and also the concentration of the 
PS into the cells (Deng et al. 2013b). 
A similar approach was developed by Peng 
et al. (Peng et al. 2013) to load the hydrophobic 
free phthalocyanine (Figure 2) into HSiNPs (Pc-
HSiNPs). The authors tested the effectiveness of 
this platform in vitro and in vivo by combing near-
infrared photodynamic therapy and photothermal 
therapy. In fact, the intratumoral injection of Pc-
HSiNPs in BALB/c mice, led to the elimination 
of the S180 murine sarcoma, after laser irradiation 
(730 nm, 1.5 W/cm2) without any significant toxic 
effects (Peng et al. 2013). The successful eradication 
was justified by the dual PDT and photothermal 
properties of Pc-HSiNPs
Tao et al. (Tao et al. 2013) also selected porous 
HSiNPs to construct a nanoplatform to deliver the 
tetrasulfonated aluminum phthalocyanine sensitizer 
(Figure 10). The loading of the phthalocyanine was 
performed in porous NPs with the surface grafted 
with polyamidoamine (PAMAM) dendrimer of 
third-generation in which was posteriorly attached 
gluconic acid (a polyhydroxylic acid) to tune 
the surface charge close to neutral (Figure 10). 
The therapeutic potential of this nanocarrier was 
evaluated in vitro using MCF-7 cells. The high 
loading and the retarded pre-release of the PS were 
justified considering the inherent structural features 
of the carrier and the functionalized outer layer 
composed by a large number of amino groups. 
These HSiNPs showed very good 1O2 generation 
ability and were also capable of inducing significant 
damage in tumor cells after irradiation with red 
light (670 nm, 8 mW/cm2). In fact, a significant cell 
death was observed for the loaded PS in HSiNPs 
(70% at 5.0 µM; 82% at 10 µM) as compared with 
free phthalocyanine tetrasulfonate (17% at 5 µM; 
35% at 10 µM) (Tao et al. 2013). 
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GOLD NANOPARTICLES
Metal NPs are also attracting a special attention 
from the scientific community due to their 
versatility in diverse areas as engineering, 
medicine, chemistry, physics and biology (Jana and 
Pal 2007, Marambio-Jones and Hoek 2010, Dos 
Santos et al. 2014, Sanvicens and Marco 2008). 
The general mechanism of metal NP action has not 
been fully understood, although it is known that 
it is necessary to obtain the correct dimensions of 
the metal NPs to avoid agglomeration, which will 
significantly reduce their biological effectiveness. 
Among all the metal NPs, gold NPs (AuNPs) 
have received particular attention, due to a 
combination of distinctive properties, which led 
them to multiple applications such as labeling, 
delivery, heating, imaging and sensing (Biju 2014, 
Castilho et al. 2015, Gupta et al. 2013, Oo et al. 
2012). Specifically, these NPs owing to their 
biocompatibility, size, unique surface and also 
optical properties have recently earned significant 
attention in PDT (Pasparakis 2013, Amini et al. 
2013, Sherwani et al. 2015). The presence of some 
functional groups such as thiol, amino and cyano, 
with high chemical affinity for AuNPs, confer them 
colloidal stability (Zeng et al. 2011). Additionally, 
the functionalization of AuNPs with biomolecules 
such as lipids, proteins, oligonucleotides or with PS 
molecules can improve their features (Castilho et 
al. 2015, Shi et al. 2004). In fact, the conjugation of 
PSs on the surface of AuNPs may increase the PDT 
efficacy due to an enhanced electromagnetic field as 
Figure 10 - Schematic representation of the preparation of a new nanoplatform to deliver the tetrasulfonated aluminum 
phthalocyanine adapted from (Tao et al. 2013).
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a result of the localized surface plasmon resonance 
of AuNPs upon light exposure. This situation will 
then lead to an efficient activation of the PS (an 
enhanced PS excitation rate) and an improvement 
of ROS production (Figure 11) (Huang and Hasan 
2014, Oo et al. 2012, Amini et al. 2013). 
In 2008, Cheng et al. (Cheng et al. 2008) 
demonstrated that pegylated AuNPs were highly 
effective drug vectors to deliver hydrophobic drugs 
for PDT like silicon phthalocyanine (Figure 12 
a). These biocompatible cages showed good and 
stable dispersion in aqueous solution allowing the 
hydrophobic drug to reach with high efficiency 
the location of PDT action, as it was demonstrated 
by the in vivo studies in cancer-bearing mice. 
The pegylated AuNPs system took less than 2 h 
to deliver the silicon phthalocyanine when it was 
conjugated with AuNPs, compared to 2 days for 
the free drug (Cheng et al. 2008). Similar results 
were obtained by Camerin et al. (Camerin et al. 
2010), which evaluated the pharmacokinetic 
and phototherapeutic properties of a zinc(II)-
phthalocyanine disulfide free and bound to AuNPs 
for the treatment of a sub-cutaneous implanted 
amelanotic melanoma in a murine tumor model 
(Figure 12b). Once again, the data showed that the 
use of these AuNPs for the delivery of hydrophobic 
PS, such as phthalocyanines, significantly enhanced 
the PDT efficacy, even though suitable approaches 
should be developed in order to limit the persistence 
of the AuNPs associated PS in important organs 
such as liver and spleen (Camerin et al. 2010).
Zhao et al. (Zhao et al. 2013a) reported the 
preparation of a theranostic platform based on 
the conjugation of a biodegradable copolymer 
with AuNPs to deliver pheophorbide a (Figure 2) 
linked to the side chain of the copolymer by an 
imine bond (Figure 13a). The phototoxicity of the 
hydrophobic pheophorbide a and of the AuNP-
PS was investigated against HeLa cells upon 
irradiation at 670 nm. This AuNPs-PS platform 
showed not only an enhanced cellular uptake and 
phototoxicity against HeLa cells when compared to 
free pheophorbide a, but also a strong fluorescence 
signal considering their use in diagnostic imaging. 
The authors justified the higher efficiency of 
AuNP-PS to the fact that NPs are improving the 
PS solubility in the aqueous environment and 
increasing 1O2 quantum yield. The replacement of 
the pheophorbide a by verteporfin (Figure 2) on 
the AuNP nanoplatform (Figure 13b) revealed even 
better uptake efficiency by HeLa cells and a marked 
photocytotoxicity when compared with the free PS 
(Zhao et al. 2016). The developed nanoplatforms 
possess drug release properties, which can be 
triggered by the pH and consequently, overcome 
the intracellular barriers of endosomal or lysosomal 
membranes that prevent the drugs to arrive to their 
targets (Zhao et al. 2013b, 2016). While stable at 
physiological pH values, the PS conjugated to the 
side chain of the copolymers, via an imine linkage 
can be released at lower pH values (4.0-6.0) like 
those found in the vicinity of tumor tissues or within 
endo/lysosomal compartments. In the reported 
example, strong fluorescence signals around the 
nucleus and in the cytoplasm of cells were observed 
for this nanoplatform which was confirmed by 
Figure 11 - Plasmonic AuNP. The local electric field caused 
by conductance electrons potentiates the optical field near the 
surface and enhances the fluorescence or photoactivity of the 
attached PS.
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Figure 13 - Structure of a biodegradable block copolymer-
AuNP conjugated with a. Pheophorbide a and b. Verteporfin.
Figure 12 - Structures of a. a silicon phthalocyanine, and b. a Zn(II)-phthalocyanine disulfide.
the cellular uptake by HeLa cells (98.62%) when 
compared to free verteporfin molecules (18.86%), 
and consequently by its marked photocytotoxicity 
(Zhao et al. 2016).
Vieira et al. (Vieira et al. 2017) also reported 
the functionalization of AuNPs with a chlorophyll 
derivative. The authors selected chlorin e6 (Ce6) 
(Figure 2) covalently linked through an amide bond 
to a thiourea molecule to perform the conjugation 
to AuNPs, and tested the photodynamic efficacy of 
the resulting nanostructures against human breast 
carcinoma cells (MDA-MB-468). The results 
showed that the photocytotoxicity of Ce6-AuNP 
was higher than Ce6 alone for MDA-MB-468 cells 
after irradiation with red light at 660 nm, but quite 
similar to the simple mixture of Ce6 with AuNPs. 
The authors commented that Ce6-AuNPs complex 
should be more efficient than the Ce6 mixture with 
AuNPs for in vivo applications because due to the 
many variables of the body circulation system there 
is no guaranty that AuNPs will be available in the 
same irradiated area of the activated Ce6 (Vieira et 
al. 2017).
The possibility to prepare a multicomponent 
system based on water-soluble AuNPs for PDT was 
recently reported by Peron et al. (Penon et al. 2017). 
This group constructed a nanoplatform of AuNPs 
(PS-AuNPs-PEG-Ab) containing a porphyrin 
derivative as PS and a polyethyleneglycol derivative 
linked to an anti-erbB2 antibody to specifically 
target the erbB2 receptors overexpressed on the 
surface of SK-BR-3 breast cancer cells (Figure 
14); the presence of the thiol groups in both ligands 
allowed a suitable functionalization of the AuNP. 
This conjugate not only proved to be successful 
in the production of 1O2 but also in the induction 
of cell death of SK-BR-3 breast cancer cells after 
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PDT irradiation. Besides the high level of cellular 
uptake, changes in the cellular morphology 
were detected and cell membrane damages were 
confirmed after irradiation of the SK-BR-3 cancer 
cells when incubated with the PS-AuNP-PEG-Ab 
conjugate (Penon et al. 2017).
In 2016, Ferreira et al. considered the 
use of two different shapes (spheres and rods) 
of gold nanostructures to prepare a colloidal 
hybrid system with the cationic derivative of 
5,10,15,20-tetrapyridylporphyrin (Figure 2) to 
be used in PDT (Ferreira et al. 2016). Based 
on electron paramagnetic resonance (EPR) 
experiments in combination with spin trapping to 
detect ROS, the authors concluded that the hybrid 
system consisting of gold nanorods (AuNR) and 
the cationic porphyrin is far more efficient than the 
isolated components. This synergetic efficiency 
was explained by a rapid energy transfer between 
the AuNR and the porphyrin producing a large 
amount of 1O2 followed by its conversion into 
hydroxyl radicals (OH●). On the other hand no 
synergetic effect was observed with the spherical 
AuNP; probably the field enhancement and the 
electrostatic attraction between the components 
of this hybrid system were not so efficient in the 
production of ROS (Ferreira et al. 2016).  
POLYMERIC MICELLES
Polymeric micelles (PMs) are one of the most 
studied drug nanocarriers that are being used 
in diagnosis and in the pharmacotherapy of 
numerous diseases. These vehicles are composed 
of amphiphilic polymers that self-assemble into 
nanostructures with sizes ranging between 10 
and 200 nm (Kwon 2003, Li and Huang 2008, 
Tong and Cheng 2007, Torchilin 2007). This 
thermodynamically driven process occurs above 
a copolymer determined concentration, commonly 
known as critical micellar concentration (CMC) 
(Croy and Kwon 2006, Riess 2003). Thus, PMs 
contain an inner hydrophobic core, in which 
poorly-water soluble-drugs can be entrapped, and 
an outer hydrophilic shell, which forms the corona 
(Figure 15) (Kwon 2003, van Nostrum 2004, 
Tong and Cheng 2007, Torchilin 2007). PMs are 
emerging as attractive nano-sized drug delivery 
systems, because they provide increased solubility 
and stability of hydrophobic drugs (Kahraman et 
al. 2015, Moretton et al. 2014), and also due to their 
in vivo benefits when compared to the free drug 
(Attia et al. 2011).
Typically, physical entrapment is achieved by 
electrostatic interaction between drug and polymer 
(the resulting particles are called polyion complex 
micelles) by dialysis from an organic solvent 
(Kakizawa and Kataoka 2002), or by oil in-water 
emulsion procedures (van Nostrum 2004). As a 
solubilizing agent for hydrophobic drugs, PMs 
possess great benefits over low molecular weight 
surfactants, as a result of the higher stability of 
the micelles. Their higher stability is due to the 
typically very low CMC of polymeric surfactants 
(Adams et al. 2003), meaning that PMs are resistant 
to dilution effects, upon for instance intravenous 
administration of the drug formulation (van 
Nostrum 2004). Another important feature of PMs 
is their small and uniform size. As aforementioned, 
particle sizes can go down to the order of 10 nm for 
non-loaded polymeric micelles. However, this size 
is still large enough to achieve passive targeting to 
tumors and inflamed tissues (Maeda et al. 2000). 
Additionally, the hydrophilic corona of PMs 
may prevent interaction with blood components. 
This situation, as well as their reduced size, will 
prevent recognition by proteins and macrophages, 
thus achieving long circulation times in the blood 
stream (Kwon et al. 1994). Moreover, it is possible 
to adjust the peripheral chain ends of the PMs with 
targeting ligands in order to try to accomplish 
active targeting and/or pH/temperature responsive 
nanocarriers (Vinogradov et al. 1999, Yasugi et 
al. 1999). Therefore, the outer hydrophilic corona 
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can be functionalized with several moieties, such 
as folate, monoclonal antibodies, monosaccharides 
(mannose, glucose, fructose), among others 
(Torchilin 2001, 2002, Zhang et al. 2014). When the 
PMs have reached their targets and for the release 
of the drugs, degradable or stimuli-responsive 
micelles have been developed (Katayama et al. 
2001, Kumar et al. 2001, Neradovic et al. 2001, 
Kakizawa et al. 1999). The role of polymeric 
micelles to improve the efficiency of several PS in 
PDT treatment is shown in some recent works that 
will be discussed below. 
For instance, Lamch et al. (Lamch et al. 2014) 
studied polymeric micelles based on a mixture of 
Pluronics P123 (EO20-PO65-EO20, MW 5800 Da) 
and F127 (EO100-PO69-EO100, MW 12600 Da) 
(Figure 16), in order to improve the photodynamic 
action of Photofrin (Figure 2) on drug resistant 
ovarian cancer cells (SKOV-3) and caspase-3 
deficient breast cancer line (MCF-7/WT) (Lamch 
et al. 2014). The cells were treated with Photofrin 
in the free form and with Photofrin encapsulated in 
PMs and were then irradiated with red light (632.5 
nm) with a light dose of 12 J/cm2 (irradiance of 10 
mW/cm2). The PMs containing Photofrin showed 
an efficient delivery inside the breast MCF-7/
WT (caspase-3 deficient) and ovarian SKOV-
3 (resistant to chemotherapy) cells and provided 
a desirable improved photodynamic activity 
and efficacy. The most significant results were 
obtained in the case of ovarian cancer, resistant 
to several cytotoxic drugs. Additionally, the low 
magnitude of hemolysis of human erythrocytes 
and the insignificant dark cytotoxicity in cancer 
cells demonstrated the high biocompatibility of 
Photofrin-loaded Pluronic micelles. The authors 
Figure 14 - Schematic representation of the PS-AuNP-PEG-Ab conjugates. AuNP 
functionalized with the thiolated porphyrin derivative ligand (red) and the thiolated 
polyethylene glycol derivative ligand (green) bound to an anti-erbB2 antibody (blue) 
adapted from (Penon et al. 2017).
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Figure 16 - Pluronic block copolymers. X is the number of 
ethylene oxide groups (EO) and Y is the number of propylene 
oxide groups (PO).
Figure 15 - Schematic representation of the micelle formation and PS-loading of amphiphilic block copolymers in water.
commented that the administration of Photofrin in 
micelles based on Pluronics (P123 and F127) could 
be extended to other resistant types of cancers since 
an increase in the cytotoxic effect after irradiation 
is easily achieved (Lamch et al. 2014).
The chloroaluminum phthalocyanine (Figure 
2) was selected by Py-Daniel et al. (Py-Daniel et al. 
2016) to be incorporated also into Pluronic F127 
micelles (F127-PS) and the efficacy of this system 
was tested against A549 human lung carcinoma 
cells. The study showed that F127-PS was able to 
produce high concentration of ROS, mainly 1O2. 
Moreover, this result was confirmed by in vitro 
assays that showed that F127-PS formulation, even 
at the tested PS loading of 0.1 µg mL-1, was very 
efficient in cell viability decreasing throughout 
light exposition (660 nm, LED light). Even 
though phthalocyanine molecules are extremely 
hydrophobic, their incorporation into optimized 
F127 micelles, provided their solubilization 
in aqueous/physiological environments, thus 
extending the range of applications of PDT with 
this PS (Py-Daniel et al. 2016). 
Lamch et al. (Lamch et al. 2016) reported the 
incorporation of the zinc(II) phthalocyanine (Figure 
2) in biodegradable and biocompatible micelles 
obtained from the block copolymer of methoxy 
poly(ethylene oxide) and poly(L-lactide) (Figure 
17) (Lamch et al. 2016). The cellular uptake and 
photocytotoxicity studies on metastatic melanoma 
cells (Me45) showed that the obtained polymeric 
micelles was able to deliver efficiently the PS to 
cancer cells, with low toxic effect towards control 
keratinocytes, macrophages, and endothelial cells. 
Depending on the loading of the PS and the dose of 
irradiation the decrease on the tumor cell viability 
attained 31%.
Another study involving the encapsulation of 
hydrophobic zinc(II) phthalocyanine was reported 
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by Debele et al. (Debele et al. 2017). The authors 
were able to synthesize pH-sensitive micelles 
from heparin polysaccharide conjugated with 
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine 
(DSPE) and L-histidine (His) (Figure 18). The 
efficacy of these micelles was evaluated in HeLa 
cells, and the results showed that they respond to 
the low intracellular pH regions of cancer cells 
or in the endosome or lysosomes. After 96 h of 
incubation, the drug release studies presented about 
91% zinc(II) phthalocyanine release from micelles 
in acidic conditions (pH 5.0) in comparison with 
63% in physiological conditions (pH 7.4). Singlet 
oxygen detection showed that micelles prevented 
the aggregation of zinc(II) phthalocyanine and 
enhanced 1O2 generation. On the other hand, 
phototoxicity experiments in HeLa cells showed 
that at higher concentrations (> 5 µM), zinc(II) 
phthalocyanine-loaded micelles were more 
cytotoxic than the free PS. In fact, more than 75% 
of HeLa cells were eradicated, which might be due 
to a better dispersion of the PS, thus diminishing 
its aggregation, and further enhancing 1O2 
generation. Hence, pH-sensitive micelles appear 
as an encouraging carrier for hydrophobic zinc(II) 
phthalocyanine, improving PDT efficacy (Debele 
et al. 2017).
In a different study, Li et al. (Li et al. 2015) 
reported the encapsulation of Photofrin (Figure 2) 
in an amphiphilic chitosan derivative conjugated 
with deoxycholic acid groups (Figure 19) using 
a simple self-assembly method in phosphate-
buffered saline solution (PBS). The efficacy of the 
resulting micelles as PSs was tested against human 
pancreatic cancer cells. It was referred that upon 
their incubation in the human pancreatic cancer 
cells, the micelles presented a higher fluorescence 
activity than the free PS and were able to generate 
higher levels of ROS under laser illumination; the 
opposite situation was observed before their cell 
incorporation. These photoactive micelles exhibited 
strong phototoxicity, which led to significant levels 
of apoptosis in the Panc-1 cells. Besides, the 
differences found in the morphologies of the cells 
treated with encapsulated and non-encapsulated 
Photofrin were in agreement with the stronger 
phototoxicity displayed by the micelles. The cells 
treated with non-encapsulated Photofrin underwent 
a gradual shrinkage whereas maintaining their 
pseudopodial structures. In contrast, the cells 
treated with the micelles shrank significantly and 
experienced membrane damage, which caused the 
loss of the initial shape of the cells (Li et al. 2015).
An interesting strategy was reported in order 
to control the PDT activity in cancer treatment.  Li 
et al. (Li et al. 2014) incorporated pheophorbide 
a (Figure 2) in polymeric micelles based on 
poly(ethylene glycol)-b-poly(caprolactone) (PEG-
b-PCL), together with β-carotene a well-known 
1O2 scavenger. The aim of the authors was that the 
presence β-carotene in the micelles would minimize 
the PS phototoxicity during blood circulation, 
but it would be maintained after internalization 
of both components into separated intracellular 
compartments of the tumor cells. The efficiency 
of these carriers, at various concentrations and 
after irradiation with light at 1.7 J/cm2, was tested 
against MCF7 cells (a human breast-cancer cell 
line) and HeLa cells and was compared with the 
one of free pheophorbide a. The studies showed 
that the physical co-incorporation of β-carotene 
and pheophorbide a did not cause FRET-based 
quenching, but the presence of β-carotene in 
the micelles was found to inhibit significantly 
1O2 generation. As it was envisaged, the 
1O2 
scavenging was inhibited when the pheophorbide a 
and β-carotene were spatially isolated through the 
Figure 17 - Structure of block copolymer of methoxy 
poly(ethylene oxide) and poly(L-lactide).
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disintegration of the micelles and the internalized 
pheophorbide a/β-carotene micelles exhibited 
remarkable phototoxicity toward tumor cells MCF7 
and HeLa cells (Li et al. 2014). 
Another interesting contribution was reported 
by Dai et al. (Dai et al. 2016). The authors developed 
a ROS sensitive drug delivery system based on 
the self-assembly of an amphiphilic polymer of 
poly(propylene sulfide)-polyethylene glycol-serine-
folic acid. The resulting micelles were loaded with 
the hydrophobic zinc(II) phthalocyanine (Figure 2) 
and the anti-cancer drug doxorubicin (DOX). The 
study showed that the physiological intracellular 
ROS and the ROS generated by the zinc(II) 
phthalocyanine under laser irradiation (1 W/cm2), 
were able to promote the disassembly of micelles 
and the anti-tumor drug release. Additionally, the 
in vitro and in vivo evaluations in a human liver cancer cell line (HepG2) revealed that these ROS 
sensitive micelles could effectively target tumor 
tissue/cells to initiate cell apoptosis and suppress 
tumor growth with minimal toxic side effect. It was 
commented that the high concentration of ROS 
produced by the PS could also be responsible by 
the efficient killing of the tumor cells.
The same concept was reported in a previous 
study by Kim et al. (Kim et al. 2016). After 
the incorporation of DOX in the copolymer 
poly(ethylene glycol)-block-poly(propylene 
sulfide) covalently linked to chlorin e6 (PPS-PEG-
Ce6) (Figure 20a) the authors demonstrated that 
chlorin e6 upon spatiotemporal irradiation, was 
able to generate ROS (such as 1O2 and adjacent 
free radicals), and consequently to induce DOX-
release triggering and endo/lysosomal rupture. 
The potentiality of the therapeutic efficacy of this 
synergistic approach was evaluated in vitro using 
human colon cancer (HCT-116) cells and in vivo 
using BALB/c mice inoculated with K-1735 cells.
Also taking in mind this dual-modality 
system for cancer treatment, Chen et al. (Chen 
et al. 2016a) encapsulated the anti-cancer drug 
DOX and the meso-tetraphenylchlorin as the PS 
in a series of thermo- and pH-responsive block 
copolymers, poly(ε-caprolactone)-b-poly[N-
isopropylacrylamide-co-N-methacryloyl-β-alanine 
(PCL-b-p(NIPAAM-co-βA)] (Figure 20b). The 
cytotoxicity study showed that PS-loaded micelle 
without light irradiation was non-toxic to HeLa 
cells. However, under light irradiation (660 nm, 
30 mW/cm2) for 6 min, the micelles showed an 
improved therapeutic efficiency by generating 1O2 
accompanied with the release of DOX (Chen et al. 
2016a).
Other recent publications using PMs as 
delivery carrier for PDT or for a combined 
therapy confirmed the high efficiency of this type 
of nanocarriers (Dehghankelishadi and Dorkoosh 
2016, Pellosi et al. 2016a, b, 2017, Zhang et al. 
2015). 
Figure 18 - Structure of a micelle composed of heparin, 
phospholipids and histidine.
Figure 19 - Structure of an amphiphilic chitosan derivative 
conjugated with deoxycholic acid groups.
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CONCLUSIONS
PDT has emerged as one important therapeutic 
option in the treatment of cancer and other non-
oncological diseases. However, despite its benefits 
over current treatments, PDT is yet to gain general 
clinical acceptance. There are several technical 
drawbacks in the application of this therapy to a wide 
range of diseases. Firstly, currently FDA approved 
PSs for PDT mainly absorb in the visible spectral 
regions below 630 nm, where light penetration into 
the skin is only a few millimeters, thus limiting 
PDT application to relatively superficial lesions. 
Secondly, it is difficulty to prepare pharmaceutical 
formulations that enable parenteral administration 
since most existing PSs are hydrophobic and simply 
aggregate under physiological conditions. Finally, 
the PS selectivity to diseased tissues is frequently 
not sufficiently high as required for clinical 
applications, exhibiting among other drawbacks, 
prolonged skin sensitization.
Therefore, the application of NPs in the field 
of PDT proposes resolutions to some of these 
difficulties and has great importance to the further 
development of this therapy. Although, much more 
research work is still required. Very few clinical 
studies have assessed the effect of the different 
delivery systems in terms of clinical efficiency. 
Beyond the laboratory Petri dish, this approach 
still needs responses such as appropriate dosage, 
delivery system and light exposure times that will 
maximize clinical effectiveness, while minimizing 
side effects.
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